# Tepha

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tepha

- Industry: Medical Devices & Equipment
- Headquarters: Lexington, US
- Website: www.tepha.com
- Total disclosed funding: $23M
- Latest round: Series C (Mar 12, 2012)
- Investors on record: 4

## About

Tepha Inc. is engaged in the development and manufacturing of advanced biomaterials focused on medical applications, particularly resorbable polymers for surgical procedures and tissue regeneration.Tepha Inc. specializes in biomaterials for medical use, particularly resorbable polymers. Headquartered in Lexington, US, the company was acquired by Becton, Dickinson & Company Platforms in July 2021 for an undisclosed amount. Tepha has received funding through a SERIES C round, raising a total of USD 11.35 mn with a current company valuation of USD 35.974 mn. The latest funding round was backed by Vertical Group.Tepha specializes in the development and manufacturing of advanced biomaterials, particularly resorbable polymers intended for use in various medical devices and surgical procedures. These products facilitate tissue regeneration and wound healing, enhancing patient outcomes while minimizing the need for follow-up surgeries. Tepha serves healthcare providers, hospitals, and medical device manufacturers primarily in North America and Europe, with applications extending across orthopedics and soft tissue repair.Tepha generates revenue through partnerships with medical device manufacturers and direct sales to healthcare institutions, primarily operating on a Business-to-Business (B2B) model. Their advanced biomaterials are supplied to medical device companies under long-term contracts, ensuring a consistent flow tailored to specific applications. The pricing reflects their premium quality, with proprietary resorbable polymers recognized for efficacy in clinical settings.Tepha Inc. plans to utilize the funds from its recent SERIES C round to support ongoing product development and market expansion efforts. Future product launches are anticipated, focusing on innovative biomaterials that address unmet medical needs. The company aims to expand its market presence in new geographic regions, targeting additional markets in North America and Europe by the end of 2023. The acquisition by Becton, Dickinson & Company Platforms will also enhance its ability to develop new solutions for healthcare professionals.

## Funding rounds

- Series C, Mar 12, 2012, $11M — Vertical Group
- Series B, Mar 11, 2009, $6M — Integra Ventures, Novartis Venture Fund, Vertical Group, Westfield Capital Management
- Series B, Feb 5, 2007, $6M — Integra Ventures, Novartis Venture Fund, Vertical Group, Westfield Capital Management

## Investors

- Integra Ventures (https://capitalatlas.ai/funds/integra-ventures) — Series B
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series B
- Vertical Group (https://capitalatlas.ai/funds/vertical-group) — Series B, Series C
- Westfield Capital Management (https://capitalatlas.ai/funds/westfield-capital-management) — Series B